Cargando…
Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma
BACKGROUND: Combination immunotherapy is now considered the standard first-line therapy for patients with metastatic clear cell renal cell carcinoma (mccRCC) after multiple clinical trials demonstrated improved overall survival compared with single-agent tyrosine kinase inhibitors. Cabozantinib modu...
Autores principales: | Li, Haoran, Sahu, Kamal Kant, Brundage, James, Benson, Mallory, Swami, Umang, Boucher, Kenneth M, Gupta, Sumati, Hawks, Josiah, Sirohi, Deepika, Agarwal, Neeraj, Maughan, Benjamin L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400129/ https://www.ncbi.nlm.nih.gov/pubmed/36952231 http://dx.doi.org/10.1093/oncolo/oyad019 |
Ejemplares similares
-
Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High‐Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial
por: Maughan, Benjamin L., et al.
Publicado: (2018) -
Avelumab, a PD‐L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma
por: Kazandjian, Dickran, et al.
Publicado: (2021) -
Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma
por: Rathi, Nityam, et al.
Publicado: (2020) -
Black Patients with Metastatic Castrate-Resistant Prostate Cancer Have a Shorter Time Interval Between PSA and Clinical Progression on Novel Hormonal Therapies plus Avelumab
por: Hawkins, Charlotte (Manogue), et al.
Publicado: (2022) -
Access to Care and Healthcare Quality Metrics for Patients with Advanced Genitourinary Cancers in Urban versus Rural Areas
por: Li, Haoran, et al.
Publicado: (2023)